| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6592904 | PFIZER | Dispersible macromolecule compositions and methods for their preparation and use |
Mar, 2014
(10 years ago) | |
| US6737045 | PFIZER | Methods and compositions for the pulmonary delivery insulin |
Mar, 2014
(10 years ago) | |
| US6423344 | PFIZER | Dispersible macromolecule compositions and methods for their preparation and use |
Mar, 2014
(10 years ago) | |
| US5997848 | PFIZER | Methods and compositions for pulmonary delivery of insulin |
Mar, 2014
(10 years ago) | |
| US6051256 | PFIZER | Dispersible macromolecule compositions and methods for their preparation and use |
Mar, 2014
(10 years ago) | |
| US6543448 | PFIZER | Apparatus and methods for dispersing dry powder medicaments |
Sep, 2014
(9 years ago) | |
| US5740794 | PFIZER | Apparatus and methods for dispersing dry powder medicaments |
Apr, 2015
(9 years ago) | |
| US6685967 | PFIZER | Methods and compositions for pulmonary delivery of insulin |
Sep, 2018
(5 years ago) | |
| US6546929 | PFIZER | Dry powder dispersing apparatus and methods for their use |
May, 2019
(4 years ago) | |
| US6257233 | PFIZER | Dry powder dispersing apparatus and methods for their use |
May, 2019
(4 years ago) | |
| US6582728 | PFIZER | Spray drying of macromolecules to produce inhaleable dry powders |
Jun, 2020
(3 years ago) | |
Exubera is owned by Pfizer.
Exubera contains Insulin Recombinant Human.
Exubera has a total of 11 drug patents out of which 11 drug patents have expired.
Expired drug patents of Exubera are:
- US6592904
- US6737045
- US6423344
- US5997848
- US6051256
- US6543448
- US5740794
- US6685967
- US6546929
- US6257233
- US6582728
Exubera was authorised for market use on 27 January, 2006.
Exubera is available in powder;inhalation dosage forms.
Exubera can be used as method of administering insulin via inhalation.
The generics of Exubera are possible to be released after 24 June, 2020.
Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient
Market Authorisation Date: 27 January, 2006
Treatment: Method of administering insulin via inhalation
Dosage: POWDER;INHALATION
EXUBERA family patents
